Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024
Rhea-AI Summary
Longeveron, a clinical stage biotechnology company (NASDAQ: LGVN), announced its participation in the Emerging Growth Virtual Conference on June 12-13, 2024. The company will present on June 12 at 1:45 p.m. ET. The presentation will be webcast and accessible via the 'Events and Presentations' section of Longeveron's website. A replay will be available for 180 days post-conference. Questions can be submitted in advance or during the event.
Positive
- Longeveron's participation in the Emerging Growth Virtual Conference increases its visibility among investors.
- The webcast and replay availability for 180 days provide extended access to the presentation, potentially attracting more investors.
Negative
- No new clinical or financial data was provided in the announcement, offering information for investors to act upon.
- The press release lacks specific details on business progress or development milestones, which could leave investors wanting more substantial updates.
News Market Reaction
On the day this news was published, LGVN gained 1.92%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
MIAMI, June 10, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will participate in the Emerging Growth Virtual Conference taking place June 12-13, 2024.
Details for the Company’s presentation:
| Date: | Wednesday, June 12, 2024 | |
| Time: | 1:45 p.m. ET |
The webcast for this conference presentation may be accessed at the “Events and Presentations” section of the Company’s website. A replay of the webcast will be available on the Longeveron website for 180 days following the conference.
Questions may be submitted in advance to Questions@EmergingGrowth.com or asked during the event.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.
Investor Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
FAQ
When is Longeveron presenting at the Emerging Growth Virtual Conference?
How can I access the Longeveron presentation at the Emerging Growth Virtual Conference?
How long will the replay of Longeveron's presentation be available?
What is Longeveron's stock symbol?
